Stocks in play: Titan Medical Inc.
Has entered into a licensing agreement with Auris Health, Inc., a Johnson & Johnson MedTech company, in respect of certain intellectual property of Titan. Under the Agreement, Titan has granted Auris Health a non-exclusive license to a portion of Titan’s IP. Titan Medical Inc. shares T.TMD are trading down $0.03 at $0.16.
Read:
Novel Mechanisms Leading the Charge in Fight Against Cancer, Opening Door to New Drugs & Therapies
Significant Oncology Results Set to be Delivered as Oral Presentations at ASCO 2023
Promising New Cancer Treatment Data to Be Presented at 2023 ASCO Annual Meeting
Global Lithium Supply Under Pressure as South American Nations Discuss "Lithium OPEC"